Welcome to our dedicated page for The Oncology Institute SEC filings (Ticker: TOI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page compiles U.S. Securities and Exchange Commission (SEC) filings for The Oncology Institute, Inc. (NASDAQ: TOI), a company focused on value-based community oncology care. Through these filings, investors can review how TOI reports its financial condition, operating results, governance changes, and certain risk factors as it delivers oncology services through clinics and affiliate locations across multiple states.
Current reports on Form 8-K provide timely disclosures about material events affecting TOI. Recent 8-K filings have covered topics such as reaffirming financial guidance and providing preliminary outlook, reporting quarterly financial results, announcing changes to the Board of Directors, and describing a cybersecurity incident affecting an information technology software provider. These filings also note the company’s Nasdaq listings for common stock under the symbol TOI and redeemable warrants under TOIIW, and they identify TOI as an emerging growth company in certain instances.
Investors looking for annual reports on Form 10-K and quarterly reports on Form 10-Q can use this page to access documents that include audited or reviewed financial statements, management’s discussion and analysis, and detailed risk factor sections. TOI’s public communications reference its Form 10-K for information on risk factors and other disclosures, which are important for understanding the context around its value-based oncology business, participation in CMS models, and use of non-GAAP metrics such as Adjusted EBITDA and Free Cash Flow.
In addition to core financial filings, this page can surface proxy statements and other governance-related documents, which describe director compensation programs, committee roles, and independence determinations, as reflected in filings related to board appointments. Filings related to non-GAAP measures also explain how TOI reconciles metrics like Adjusted EBITDA and Free Cash Flow to the most comparable GAAP measures and outline the types of adjustments used.
Stock Titan’s platform enhances these SEC filings with AI-powered summaries that highlight key points from lengthy documents. Users can quickly identify major changes in outlook, capital structure, or governance without reading every page. Real-time updates from EDGAR ensure that new 8-K, 10-Q, 10-K, and other filings for TOI appear promptly, while AI-generated explanations help clarify complex accounting adjustments, non-GAAP reconciliations, and the implications of items such as cybersecurity disclosures or changes in board composition.
Oncology Institute (TOI) Chief Executive Officer Daniel Virnich reported an insider equity award. The Form 4 shows 6,211 shares of common stock acquired at $0.00 on 11/12/2025, reflecting RSUs that were fully vested upon grant and settled net of withholding taxes. Following this transaction, he beneficially owned 1,793,520 shares, held directly.
Oncology Institute, Inc. (TOI) insider activity: A Form 4 reports that the company’s Chief Medical Officer acquired common stock via restricted stock units (RSUs) that were fully vested upon grant on 11/12/2025.
The filing lists two RSU-related acquisitions at a price of $0.00 per share: 306 shares and 1,202 shares, reported as net of withholding tax obligations. Following these transactions, the reporting person beneficially owned 235,844 shares.
The Oncology Institute, Inc. (TOI) furnished an investor presentation under Item 7.01 (Regulation FD) via an 8-K. The presentation, dated November 14, 2025, is attached as Exhibit 99.1. TOI states this information is furnished, not filed, so it is not subject to Section 18 liabilities and is not incorporated by reference into Securities Act or Exchange Act filings. TOI’s securities trade on Nasdaq under TOI (common stock) and TOIIW (redeemable warrants).
The Oncology Institute, Inc. (TOI) reported Q3 2025 results with total operating revenue of $136.6 million, up from $99.9 million a year ago, driven mainly by dispensary sales. Dispensary revenue reached $75.9 million versus $48.2 million, while patient services were $60.2 million versus $49.8 million. Capitated revenue was $20.6 million versus $14.8 million.
The company posted a Q3 loss from operations of $8.1 million, improving from a $13.9 million loss, and a net loss of $16.5 million. Year‑to‑date revenue was $360.8 million with a net loss of $53.1 million. Cash and cash equivalents were $27.7 million at quarter‑end, and net cash used in operations was $27.8 million for the nine months.
TOI reduced SG&A and executed financing actions: a $20.0 million partial prepayment of its Senior Secured Convertible Notes and removal of the $40.0 million minimum cash covenant; approximately $16.5 million in gross proceeds from a private placement; and $11.8 million in aggregate gross proceeds under its at‑the‑market program, including 3.4 million shares sold in Q3. Long‑term debt was $76.2 million, and stockholders’ equity was a deficit of $12.3 million. Management concluded it has sufficient liquidity for at least one year.
The Oncology Institute, Inc. filed a current report stating that it issued a press release announcing its financial results for the three months ended September 30, 2025.
The company furnished the press release as Exhibit 99.1, which includes details about its results of operations and financial condition for the quarter, along with other financial information. The company notes that this information is being furnished rather than filed under the Exchange Act, which affects how it is treated for certain legal purposes.
The Oncology Institute (TOI) reported a third‑party cybersecurity incident affecting an external software provider that is expected to cause a brief, immaterial delay in fee‑for‑service collections. The company said there is no indication from the provider that any patient personal information was compromised, and the investigation is ongoing.
TOI is working with the provider to mitigate impacts and restore normal billing operations. The disclosure was furnished under Regulation FD.